A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Clinical trial NCT07458347 · RECRUITING

Trial details

NCT number: NCT07458347
Sponsor: Kestrel Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)Other KRAS-mutant Solid Tumors

Start date: 2026-04-21
Primary completion: 2027-06-01
Enrollment: 145

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.